A

Amgen

Makes biotech medicines for serious illnesses

Engineer 1 - Maintenance

Full-TimeUpdated on 10/23/2026
No salary listed
Junior, Mid
Bachelor's, Master's, Associate's
Singapore
In PersonOn-site in Tuas, Singapore.
Mechanical EngineeringMechanical Maintenance and Reliability Engineering

About the job

Requirements
  • A master's degree, or a bachelor's degree and 2 years of directly related experience, or an associate's degree and/or 4 years of directly related experience, or a high school diploma/GED and 6 years of directly related experience.
  • Strong technical knowledge of utilities, mechanical maintenance, maintenance execution, and equipment troubleshooting in a Good Manufacturing Practice (GMP) manufacturing environment.
  • Ability to provide technical oversight, influence maintenance execution, and guide technicians and contractors without direct people-management accountability.
  • Strong analytical and science-based problem-solving skills, including supporting troubleshooting, Root Cause Analysis, Corrective and Preventive Action (CAPA) implementation, and continuous improvement.
  • Proven experience working in a GMP environment, with awareness of safety, compliance, documentation, and maintenance quality requirements.
  • Experience managing contractors, vendors, and third-party service providers for routine, non-routine, and improvement maintenance activities.
  • Ability to communicate complex technical ideas clearly and practically to non-engineering stakeholders.
  • Ability to work effectively with Manufacturing, Maintenance, Engineering, Quality, EHS, Planning and Scheduling, System Owners, contractors, and vendors.
Responsibilities
  • Provide field-based technical oversight for utilities and mechanical maintenance, including equipment walkdowns, live troubleshooting, work execution support, and technical resolution of mechanical equipment issues at the job site.
  • Drive maintenance and improvement activities by prioritizing field issues, following up on preventive maintenance execution, verifying job completion quality, and ensuring improvement actions are practical, executable, and effective at equipment level.
  • Collaborate with System Owners and Technicians to troubleshoot in the field, review equipment condition, investigate recurring failures, improve reliability, and strengthen preventive maintenance tasks and job plans using maintenance execution feedback.
  • Work with Planning and Scheduling to ensure work orders are field-ready, properly scoped, resourced, and executable within available maintenance windows.
  • Confirm job scope, required materials, permits, isolation needs, access constraints, and field readiness for routine and non-routine maintenance activities with Maintenance Planners and Schedulers.
  • Coordinate daily execution with Technicians and Utility Operations, including field walkdowns, job-start readiness, technical support during work, and post-work verification against safety, compliance, quality, and delivery expectations.
  • Provide on-the-floor technical guidance to Technicians during complex mechanical maintenance, support troubleshooting decisions, verify work quality, and escalate technical, compliance, or resource concerns.
  • Gather Technician feedback after job execution, review recurring field issues, and improve job plans, work instructions, procedures, tools, and spare parts based on maintenance experience.
  • Support troubleshooting, condition assessment, maintenance execution, and reliability improvement for mechanical and utilities equipment, including pumps, motors, fans, agitators, mechanical seals, valves, piping systems, HVAC, air handling units, heat exchangers, chillers, cooling towers, boilers, steam generators, air compressors, and pressure vessels.
  • Participate in Root Cause Analysis and problem solving using field observations, equipment history, Technician input, failed-part inspection, and job execution feedback to develop reliability improvements.
  • Initiate and support deviations related to Utilities operations, Maintenance, and Calibration by gathering field facts, maintenance records, equipment-condition evidence, and Technician input, and supporting associated CAPA execution.
  • Ensure maintenance work is executed and documented in accordance with Good Documentation Practice, including accurate field records, work order closeout, and computerized maintenance management system (CMMS) updates.
  • Develop and improve maintenance procedures, work instructions, and job plans based on field execution feedback, equipment walkdowns, Technician input, and recurring maintenance issues.
  • Develop, implement, and continuously improve technical training, qualification programs, and individual competency roadmaps for maintenance personnel in calibration and electrical disciplines, ensuring competency progression, GMP compliance, and alignment with site operational needs.
  • Capture and share practical maintenance knowledge from field troubleshooting, lessons learned, recurring failures, equipment walkdowns, best practices, technical standards, and Technician experience to support knowledge retention and workforce capability development.
  • Assess Technician technical proficiency through field observations, practical assessments, and coaching engagements to identify technical gaps, development opportunities, and qualification support needs.
  • Coordinate and oversee contractors and vendors during field execution, including job-scope confirmation, site readiness, work-quality checks, technical issue resolution, knowledge transfer, and post-work verification.
  • Define contractor technical expectations and assess contractor work quality during major maintenance activities, shutdown support, field execution, and post-work verification.
  • Support project handover, commissioning, qualification, system walkdowns, punch-item closure, critical component identification, spare-parts identification, and maintenance-plan development for new or modified systems.
  • Develop, execute, and perform work safely in accordance with Amgen safety requirements, including lockout/tagout, Job Hazard Analysis, risk assessment, safe work procedures, and applicable EHS expectations.
Desired Qualifications
  • Experience with computerized maintenance management system (CMMS) work order management, preventive maintenance, job plan improvement, maintenance procedures, and schedule coordination.
  • Experience developing or supporting technical training frameworks, qualification programs, Technician competency assessments, knowledge repositories, or contractor technical governance programs.
  • Knowledge of digital and analytical tools such as Excel, Power BI, Tableau, Smartsheet, Spotfire, or similar tools.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.